With beginning of 2021 Glycotope will offer its Contract Development Organization (CDO) and Clinical Lab services under the brand name FyoniBio®, the service branch of Glycotope.
With 20 years of history in biopharma development FyoniBio® is in a…
Enhancement of Target Cell Killing for Innovative Therapies
Researchers from the MDC and Charité have developed a new gene therapy based around a special T-cell receptor that helps the immune system effectively recognize and fight cancer cells. The safety of the novel therapy is now being tested on patients…
GILUPI GmbH and SCIENION AG announced on March 18that the companies intend to intensify their collaboration in the field of single circulating tumor cell (CTC) analysis. CTCs are rare cells that can be found in the peripheral blood of cancer…
Cardio-microcurrent device for chronic heart failure: first-in-human clinical study
Most devices for treating ambulatory Class II and III heart failure are linked to electrical pulses. However, a steady electric potential gradient is also…
Lab to market is a program for researchers in
Advanced Materials. If you are considering commercialising your technology, this program is for you.
We aim to turn scientists into science entrepreneurs.
Are you doing research in Advanced…
The Advanced Materials Competition (AdMaCom) is a fast-paced 2 week Accelerator Program for Startups in Advanced Materials.
AdMaCom focuses on: IP Strategy, Investment & funding opportunities, Technical & Business Mentoring, Pitch training and…
Rubbers & plastics for the automotive industry
SCIENION AG, located in the Technology Park Adlershof since its foundation in 2001, today announced that the expanding company will build larger new headquarters at Wagner-Régeny Street in the same district of Berlin.
• Proceeds will facilitate development of GeneQuine’s gene therapy pipeline for musculoskeletal disorders and vector platform
• Lead gene therapy candidate GQ-303, a potentially disease-modifying treatment for osteoarthritis, will be advanced to…
